Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Is Composing Emerging Markets Strategy: Latest Acquisition Is Brazilian Medley For $686M

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi’s acquisition of Medley, Brazil’s largest generics company, reinforces its increasingly aggressive expansion in emerging markets.

Related Content

Sanofi Finalizes Zentiva Sale With Focus Back On Turnaround
Sanofi Channel Stuffing In Brazil?
Emerging Markets Earnings Roundup: Sanofi Channel Stuffing In Brazil? (Part 4)
Emerging Markets Earnings Round Up: Sanofi And BMS (Part 6)
Sanofi Growth Slows In Emerging Markets But South America Accelerates: Emerging Markets Earnings Round Up (Part 2)
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)
South of the Border: Sanofi’s Tailored Approach To Emerging Markets
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer
Deals Of The Week: BMS/Otsuka, Merck/Cardiome, Sanofi/Medley





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts